1. Home
  2. CTOR vs SKYE Comparison

CTOR vs SKYE Comparison

Compare CTOR & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTOR
  • SKYE
  • Stock Information
  • Founded
  • CTOR 2021
  • SKYE 2012
  • Country
  • CTOR United States
  • SKYE United States
  • Employees
  • CTOR N/A
  • SKYE N/A
  • Industry
  • CTOR
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTOR
  • SKYE Health Care
  • Exchange
  • CTOR NYSE
  • SKYE Nasdaq
  • Market Cap
  • CTOR 89.9M
  • SKYE 80.7M
  • IPO Year
  • CTOR N/A
  • SKYE N/A
  • Fundamental
  • Price
  • CTOR $1.18
  • SKYE $3.14
  • Analyst Decision
  • CTOR Strong Buy
  • SKYE Buy
  • Analyst Count
  • CTOR 2
  • SKYE 6
  • Target Price
  • CTOR $4.50
  • SKYE $18.67
  • AVG Volume (30 Days)
  • CTOR 85.3K
  • SKYE 178.7K
  • Earning Date
  • CTOR 02-21-2025
  • SKYE 02-18-2025
  • Dividend Yield
  • CTOR N/A
  • SKYE N/A
  • EPS Growth
  • CTOR N/A
  • SKYE N/A
  • EPS
  • CTOR N/A
  • SKYE N/A
  • Revenue
  • CTOR N/A
  • SKYE N/A
  • Revenue This Year
  • CTOR N/A
  • SKYE N/A
  • Revenue Next Year
  • CTOR N/A
  • SKYE N/A
  • P/E Ratio
  • CTOR N/A
  • SKYE N/A
  • Revenue Growth
  • CTOR N/A
  • SKYE N/A
  • 52 Week Low
  • CTOR $0.85
  • SKYE $2.31
  • 52 Week High
  • CTOR $49.00
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • CTOR N/A
  • SKYE 52.82
  • Support Level
  • CTOR N/A
  • SKYE $2.70
  • Resistance Level
  • CTOR N/A
  • SKYE $3.29
  • Average True Range (ATR)
  • CTOR 0.00
  • SKYE 0.45
  • MACD
  • CTOR 0.00
  • SKYE 0.05
  • Stochastic Oscillator
  • CTOR 0.00
  • SKYE 41.27

About CTOR CITIUS ONCOLOGY INC

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: